Technical CommentsCancer

Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”

See allHide authors and affiliations

Science Translational Medicine  24 May 2017:
Vol. 9, Issue 391, eaam6298
DOI: 10.1126/scitranslmed.aam6298


  • Fig. 1. qPCR analysis of OCT2 transcription in RCC.

    RNA was extracted from 38 pairs of RCC and adjacent nontumor tissue samples. Peptidylprolyl isomerase A (PPIA) was used as the reference gene to normalize OCT2 expression in collected tissue samples.

  • Fig. 2. Representative images of IHC staining for OCT2 protein.

    (A) IHC staining in different tissues using antibody AMAb90791. Data were cited from HPA database. Scale bars, 100 μm. (B) Immunostaining of OCT2 in RCC tissues using AMAb90791 antibody. Left, normal kidney tissues; right, RCC tissues. Scale bars, 100 μm. (C) Immunostaining for OCT2 using two different antibodies (MAB6547 and AMAb90791) in RCC and adjacent nontumor tissues. Upper image scale bars, 50 μm; lower image scale bars, 100 μm.

  • Fig. 3. Validation of OCT2 protein expression in RCC.

    (A) Representative images of immunoblots in four pairs of RCC and adjacent nontumor tissues using antibody HPA008567. (B) qPCR analysis of OCT2 transcription in tissues shown in (A). (C) Immunoblots using antibody HPA008567 in knockdown cell line lysates from stable ectopic OCT2-expressing cell line. MDCK-OCT2 was used as a positive control to indicate the true signal. RCC cell lines expressing OCT2-specific shRNA (shOCT2-03) were treated with 2.5 μM DAC for 72 hours. shNC (negative control) was used as nontargeting shRNA.

  • Fig. 4. MATE1 transcription in RCC.

    (A) Meta-analysis of MATE1 transcription in RCC tissues using data sets from the Oncomine database, one-tailed unpaired t test ( (B) qPCR analysis of MATE1 transcription in RCC cell lines. RCC cell lines were treated with DAC (2.5 μM) in RCC cells. ND, not detected.

Navigate This Article